M&a

(Image: Getty/Robert Daly)

UCB set to buy Ra Pharma for $2.1bn

By Ben Hargreaves

With both boards of directors in agreement, UCB is on track to add the clinical stage biopharma company and its lead drug candidate, zilucoplan, to its portfolio.

(Image: Getty/kritchanut)

Guest column

M&A in the CRO industry: The Good, The Bad, and The Ugly

By Matthew Barrows, senior business consultant

M&A is a huge part of the CRO space. Inorganic growth has long been the go-to strategy for any CRO and we’re never surprised to see this month’s latest deal. However, I’d like to challenge the idea that this is always the best way to grow a CRO business.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers